Title: A novel KCNJ11 mutation associated with transient neonatal diabetes

Short Running Title: A case of transient neonatal diabetes

Authors: Evangelia Gole1, Stavroula Oikonomou1, Sian Ellard2, Elisa De franco2, Kyriaki Karavanaki1

Institutions: 1Athens Medical School, 2nd Department of Pediatrics, Athens, Greece
2University of Exeter Medical School, Institute of Biomedical and Clinical Science, Exeter, United Kingdom

Manuscript Type: Case Report

Corresponding author and reprints requests: K. Karavanaki

Address for correspondence:
Kyriaki Karavanaki, MD PhD,
Associate Professor in Pediatrics and Pediatric Diabetes,
Second University Department of Pediatrics, “P. & A. Kyriakou” Children"s Hospital, Goudi 11527, Athens, Greece
Tel: +30-210-7726488; Fax: +30-210-777-4383; e-mail: kkarav@yahoo.gr

Grants: The genetic studies were funded by Wellcome Trust Senior Investigators Award to SE.

What is already known on this topic?

- Neonatal diabetes is a monogenic disorder presenting as a transient or permanent type.
- Transient cases are usually due to abnormalities in the 6q24 region, while some patients may have mutations in the KCNJ11 and ABCC8 genes.
What this study adds?

- We describe a novel \( \text{KCNJ11} \) gene mutation (p.P254Q) in a patient with neonatal diabetes that subsided at the age of 10 months.

- The p.P254Q mutation seems to cause mild impairment of the \( K_{\text{ATP}} \) channel function leading to transient neonatal diabetes.

Abstract

**Background**: Neonatal diabetes mellitus (NDM) is a rare type of monogenic diabetes that presents in the first 6 months of life. Activating mutations in the \( \text{KCNJ11} \) gene encoding for the Kir6.2 subunit of the \( K_{\text{ATP}} \) channel can lead to transient (TNDM) or permanent neonatal diabetes mellitus (PNDM).

**Case report**: A female infant presented at the 22\(^{nd}\) day of life with severe hyperglycemia and ketoacidosis (glucose: 907mg/dl, blood gas pH: 6.84, \( \text{HCO}_3^- \): 6mmol/l). She was initially managed with intravenous (IV) fluids and IV insulin. Ketoacidosis resolved within 48 hours and she was started on subcutaneous insulin injections with intermediate acting insulin NPH twice daily requiring initially 0.75-1.35 IU/kg/d. Pre-prandial C-peptide levels were 0.51 ng/ml (normal: 1.77-4.68). Insulin requirements were gradually reduced and insulin administration was discontinued at the age of 10 months with normal subsequent glucose and \( \text{HbA1c} \) levels. C-peptide levels normalized (pre-prandial: 1.6 ng/ml, postprandial: 2 ng/ml). Genetic analysis identified a novel missense mutation (p.Pro254Gln) in the \( \text{KCNJ11} \) gene.

**Conclusion**: We report a novel \( \text{KCNJ11} \) mutation in a patient who presented in the first month of life with a phenotype of NDM that subsided at the age of 10 months. It is likely that the novel p.P254Q mutation results in mild impairment of the \( K_{\text{ATP}} \) channel function leading to TNDM.

**Keywords**: neonatal diabetes, \( \text{KCNJ11} \), hyperglycemia, transient

Introduction

Neonatal diabetes mellitus (NDM) is a rare type of monogenic diabetes, which presents usually before the age of 6 months (1). To date, abnormalities in 23 genetic loci have been associated with NDM (2, 3, 4). Clinically, NDM can be classified in two major categories, transient neonatal diabetes mellitus (TNDM) and permanent neonatal diabetes mellitus (PNDM). The reported incidence of NDM is quite variable and is lower in western countries [Italy: 1 in 90,000 live births (5), UK: 1 in 400,000 (6)] and higher in eastern countries [1 in 21,000 in Saudi Arabia (7)], with high rates of consanguinity. Turkey (particularly in South-Eastern Anatolian regions) has a high rate of consanguineous marriages (40%) and PNDM incidence is reported to be 1 in 48,000 live births (8).

TNDM accounts for approximately 50% of the cases of neonatal diabetes. Children with TNDM are usually born with intrauterine growth retardation (IUGR) and tend to
develop diabetes in the first weeks of life (9). Diabetes subsides in the following months, with a possible relapse to a permanent state during puberty or adult life. About 70% of TNDM cases are due to abnormalities in the 6q24 region, with the remainder of patients having mainly mutations in the \textit{KCNJ11} and \textit{ABCC8} genes encoding the Kir6.2 and SUR1 subunits of the pancreatic K\textsubscript{ATP} channel (10). This channel regulates insulin secretion by linking glucose metabolism and consequent ATP production to calcium-dependent release of insulin. Activating \textit{KCNJ11} or \textit{ABCC8} mutations lead to inappropriate activation of the K\textsubscript{ATP} channel, thereby compromising membrane depolarization and insulin secretion (11). Some of these mutations have been reported to have less severe effects on channel function, causing TNDM (12).

In children with PNDM, diabetes does not remit, and about half of them have K\textsubscript{ATP} channel mutations (1). There is significant clinical overlap between the two types of neonatal diabetes and it is therefore not possible to predict the clinical course at the time of diagnosis. Sulfonylureas have inactivating effects on the K\textsubscript{ATP} channel, hence most of the patients with confirmed \textit{KCNJ11} and \textit{ABCC8} mutations may discontinue insulin and be successfully managed with oral sulfonylureas (13). In this article, we describe a case of TNDM due to a novel mutation in the \textit{KCNJ11} gene.

**Case report**

A female infant was born to a single mother of Pakistani origin at 38 weeks of gestation. The mother was a refugee and had under her care another three healthy children (age: 8, 5, and 2.5 years old), while the presumed father presented type 2 diabetes mellitus (T2DM) at the age of 30 years, as well as many members of his family. The mother had inadequate antenatal care during this pregnancy. Delivery was uneventful and the infant had no dysmorphic features. Birth weight was 2500 gr (-2 standard deviations according to WHO growth charts). The patient was admitted to hospital at the age of 22 days, with respiratory distress and signs of severe dehydration. Diagnostic work-up revealed hyperglycemia with severe ketoacidosis (glucose: 907mg/dl, blood gas pH: 6.84, HCO\textsubscript{3}: 6mmol/l), that was managed with intravenous (IV) fluids and IV insulin administration. In addition, due to the patient’s critical condition, the possibility of infection was also considered, and the appropriate infection laboratory work-up was performed, followed by IV antibiotic administration, which were discontinued with the results of negative blood cultures. **HbA1c levels on admission were 7.5% (RR:4.0-6.0%).** Due to the patient’s age (less than 6 months) and the laboratory findings of severe hyperglycemia and ketoacidosis, the diagnosis of NDM was considered. The infant recovered from ketoacidosis within 48 hours and was started on subcutaneous insulin with intermediate acting insulin NPH twice daily, requiring initially 0.75-1.35 IU/kg/d. Blood glucose levels raised significantly after breastfeeding, therefore it was decided to start feeding with specific amounts of expressed breast milk at 150 ml/kg/day. With this regimen, hyperglycemia was well controlled with no episodes of hypoglycemia (blood glucose levels ranging between 91-109 mg/dl). Further investigations did not reveal any signs of autoimmunity with negative anti-GAD (antibodies against glutamic acid decarboxylase) (0.2 U/ml, RR:<0.9) and anti-IA2 (antibodies against tyrosine phosphatase) (<0.1 U/ml, RR<0.75), while cardiological, ophthalmological and neurological examinations were normal. At the time of diagnosis C-peptide was low (0.51 ng/ml, RR: 1.77-4.68).

During patient’s regular follow-up, insulin requirements were gradually reduced and at the age of 8 months the patient was requiring 0.32 mg/kg/day of insulin NPH achieving normoglycemia (HbA1c:5.4 %, RR:4.0-6.0%). Growth and psychomotor development were normal (weight: 50\textsuperscript{th} percentile, height: 75\textsuperscript{th}-90\textsuperscript{th} percentile, head circumference: 25-50\textsuperscript{th} percentile). Informed consent was obtained from patient’s mother for genetic analysis and
publication of the results. Sanger sequencing analysis of the ABCC8, KCNJ11, INS and EIF2AK3 genes identified a novel missense variant in the KCNJ11 gene p.Pro254Gln (p.P254Q) (Figure 1). This variant has not been reported before and is not listed in HGMDpro. In addition, the variant has not been identified in 138,487 individuals in the GnomAD database (http://gnomad.broadinstitute.org/). Testing of all the other known neonatal diabetes genes by targeted next generation sequencing (3) was negative, confirming that this was the only likely pathogenic variant identified in our patient. In silico analysis by SIFT and PolyPhen2 was performed that predicts this mutation to affect the protein’s function.

The p.P254Q mutation was not detected in the mother’s sample, however the presumed father denied genetic testing. Trial of treatment with oral sulfonylureas was decided; however, at the age of 10 months, diabetes remitted and insulin injections were discontinued by the mother before initiating the scheduled sulfonylurea treatment protocol. Blood glucose levels remained at the normal range without any treatment, HbA1c (4.9%, RR=4.0-6.0%) and C-peptide levels had normalized (pre-prandial: 1.6 ng/ml, postprandial: 2 ng/ml; RR:1.1-4.4). During the following three months after insulin discontinuation her HbA1c levels (5.2%, RR=4.0-6.0%) and blood glucose measurements remained normal.

Discussion

We report a patient with NDM caused by a novel heterozygous KCNJ11 mutation. Although the p.P254Q mutation has not been reported before, the phenotype of our patient, along with the fact that no mutations were found in the other known NDM genes, supports the pathogenicity of the mutation. This novel mutation (c.761C>A, p.P254Q) leads to the substitution of the non-polar proline at codon 254 to a polar glutamine in the cytoplasmic domain of the KATP channel. The proline residue at position 254 is highly conserved across species (up to C.Elegans, 23 species considered) and is predicted to be pathogenic by SIFT and PolyPhen2 as described above.

More than 30 activating KCNJ11 mutations have been associated with NDM so far (1). These mutations in their majority seem to affect KATP channel’s sensitivity to ATP and impair its function. Mutated KATP channels show reduced sensitivity to ATP inhibition, resulting in membrane hyperpolarization and impaired insulin secretion (14). Mutations within the ATP-binding site are known to be associated with milder phenotypes, whilst mutations located in areas responsible for channel opening and closure, affect ATP sensitivity indirectly and cause a more severe phenotype (15). The extent of membrane hyperpolarization caused by each mutation can explain the spectrum of variation of the clinical phenotype of the disease, ranging from TNDM (16) to PNDM with neurological complications (DEND syndrome-developmental delay, epilepsy and neonatal diabetes) (15). Our patient has normal psychomotor development.

On the other hand, less severe KCNJ11 mutations result in remitting/relapsing neonatal diabetes, Maturity Onset Diabetes of the Young (MODY) or T2DM in an older age (10). These mutations usually result in mild impairment of KATP channel function, as has been shown for the p.V252A mutation (17), that is located just 2 amino acids apart from the mutation identified in our patient. The mechanism proposed to explain these phenotypes suggests that there is a mild beta cell defect caused by some mutations, that may be compensated transiently, and hyperglycemia may present again in periods of increased insulin requirements (16, 18). Although we were not able to perform a functional study, considering the phenotype of our patient, we can hypothesize that the mutation identified in our patient causes a mild reduction in channel sensitivity to ATP. Likewise, our patient’s presumed
father developed T2DM at the age of 30 years, however, as he denied genetic analysis, we do not know if he has the same mutation with our patient.

Managing infants with NDM encounters many problems, arising from the very small insulin doses required, the high risk of hypoglycemia, the lack of subcutaneous fat and the coordination of insulin therapy with the frequent and uncontrolled feeding of the newborn period. Continuous subcutaneous insulin infusion (CSII) has been recommended as the treatment of choice in the initial management of infants with NDM (19,20,21). Rapid acting insulin preparations (Lispro, Aspart and Regular) may cause severe hypoglycemia and should be avoided, with the exception of CSII (1), while long acting or intermediate acting insulin have been successfully used in these patients (22, 23,24). In our case, due to the poor socioeconomic and educational background of our patient’s family, she was successfully managed with subcutaneous injections of insulin NPH, and achieved very good metabolic control with no significant glycemic variability and optimal growth and development.

Sulfonylurea is the treatment of choice in patients with KCNJ11 or ABCC8 mutations (13,25). Thus after genetic identification of a mutation in one of these genes, more than 400 patients have been successfully transferred from insulin to sulfonylurea and most of them responded well with improved glycemic control and less hypoglycemic events (25). In our case, diabetes remitted, before the planned sulfonylurea treatment initiation.

In conclusion, we report the case of an infant with transient neonatal diabetes associated with a novel mutation of the KCNJ11 gene. Diabetes remitted after 10 months with an uneventful course and good psychomotor development under subcutaneous insulin regimen. Studies describing the genotype-phenotype correlation of novel mutations can help clinicians to predict the severity of the disease and appropriately manage these patients.

**Conflict of interest statement:** Authors declare there is no conflict of interest.
References:


**Figure 1.** Sanger sequencing analysis of the KCNJ11 gene. Detection of a novel mutation, c.761C>A (p.P254Q), in the proband.